<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01271348</url>
  </required_header>
  <id_info>
    <org_study_id>XPM-032</org_study_id>
    <nct_id>NCT01271348</nct_id>
  </id_info>
  <brief_title>Study of Etoricoxib for the Treatment of Muscle Pain and Inflammation Induced by Eccentric Exercise</brief_title>
  <official_title>Multiple-dose, Randomized, Double Blinded, Placebo-controlled, Cross Over Study of Etoricoxib for the Treatment of Muscle Pain and Inflammation Induced by Eccentric Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>X-pert Med GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>X-pert Med GmbH</source>
  <brief_summary>
    <textblock>
      Comparison of the effect of etoricoxib to placebo on muscle pain caused by eccentric&#xD;
      contractions&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain during muscle contraction</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Muscle Pain</condition>
  <arm_group>
    <arm_group_label>Etoricoxib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoricoxib</intervention_name>
    <description>Etoricoxib film tablet, 90 mg, q.d.</description>
    <arm_group_label>Etoricoxib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo tablet, q.d.</description>
    <arm_group_label>Placebo tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated informed consent prior to participation&#xD;
&#xD;
          -  Subjects in good health as determined by the Investigator&#xD;
&#xD;
          -  Age 18-40 or 50-70&#xD;
&#xD;
          -  BMI &gt; 20 and &lt; 30&#xD;
&#xD;
          -  Pain in the target muscle (thigh) during muscle contraction of at least 5 on an 11&#xD;
             point categorical pain rating scale&#xD;
&#xD;
          -  Willing to abstain from any physical therapy, hard physical work, exercise or sauna&#xD;
             during the study treatment periods (Screening to Final Visit)&#xD;
&#xD;
          -  For females, subjects of childbearing potential (including peri-menopausal women who&#xD;
             have had a menstrual period within 1 year) must be using appropriate birth control&#xD;
             (defined as a method which results in a low failure rate, i.e., less than 1% per year&#xD;
             when used consistently and correctly, such as implants, injectables, some intrauterine&#xD;
             contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner). Oral&#xD;
             contraceptive medications are not allowed in this study. Female subjects, who are&#xD;
             surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy)&#xD;
             are allowed for participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in another clinical study within the last 30 days and during the study&#xD;
&#xD;
          -  Subjects who are inmates of psychiatric wards, prisons, or other state institutions&#xD;
&#xD;
          -  Investigator or any other team member involved directly or indirectly in the conduct&#xD;
             of the clinical study&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Alcohol or drug abuse&#xD;
&#xD;
          -  Malignancy within the past 2 years with the exception of in situ removal of basal cell&#xD;
             carcinoma&#xD;
&#xD;
          -  Known hypersensitivity to etoricoxib or other NSAIDÂ´s including Cox-2, or any of their&#xD;
             excipients&#xD;
&#xD;
          -  Bronchospasm, acute rhinitis, nasal congestion, angioneurotic edema, urticaria or&#xD;
             allergic reactions after taking aspirin or other NSAIDs including Cox-2 inhibitors&#xD;
&#xD;
          -  Major traumatic lesions (e.g. fracture, tendon or muscle ruptures) of the&#xD;
             musculo-sceletal system of the lower limbs&#xD;
&#xD;
          -  Pain conditions which might interfere with pain rating during the study, e.g.&#xD;
             neuropathic pain&#xD;
&#xD;
          -  Significant neurological or psychiatric symptoms resulting in disorientation, memory&#xD;
             impairment, or inability to report accurately (e.g. depressive disorders, Alzheimer's&#xD;
             disease, schizophrenia or other psychosis), that in the investigator's opinion may&#xD;
             affect efficacy or safety assessments or may compromise subject safety during the&#xD;
             study&#xD;
&#xD;
          -  Heart failure (NYHA II-IV)&#xD;
&#xD;
          -  Long term blood pressure &gt; 140/90 mm Hg without adequate treatment&#xD;
&#xD;
          -  Peripheral arterial disease, coronary heart disease and/or cerebrovascular disease&#xD;
&#xD;
          -  History of stroke or myocardial infarction&#xD;
&#xD;
          -  Clinically relevant ECG changes&#xD;
&#xD;
          -  Estimated creatinine clearance &lt; 60 ml/min&#xD;
&#xD;
          -  Liver dysfunction (e.g. defined by ALT and/or AST levels above upper limit of normal&#xD;
             range)&#xD;
&#xD;
          -  Coagulopathy or bleeding diathesis, or concomitant use of anticoagulants including low&#xD;
             dose aspirin&#xD;
&#xD;
          -  History of pancreatitis, peptic ulcers or gastrointestinal bleedings&#xD;
&#xD;
          -  Inflammatory GI disease (e.g. M. Crohn, colitis ulcerosa)&#xD;
&#xD;
          -  Any other analgesic therapy including cough and cold drugs containing analgesic&#xD;
             properties as well as any other substance used for the treatment of pain during the&#xD;
             study observation period (Screening to final Visit)&#xD;
&#xD;
          -  Any other drug that might alter pain perception like CNS active drugs&#xD;
&#xD;
          -  Statins within 3 months of screening and throughout the study&#xD;
&#xD;
          -  Oral anticonceptives&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Rother, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Director Clinical Operations</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>X-pert Med GmbH</name>
      <address>
        <city>Jena</city>
        <zip>07745</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>January 5, 2011</study_first_submitted>
  <study_first_submitted_qc>January 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2011</study_first_posted>
  <last_update_submitted>October 31, 2011</last_update_submitted>
  <last_update_submitted_qc>October 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myalgia</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoricoxib</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 15, 2012</submitted>
    <returned>March 5, 2012</returned>
    <submitted>March 6, 2012</submitted>
    <returned>April 3, 2012</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

